Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604366 | 0.82 | KIF11 (0.31) | KIF11 | |
| SCHEMBL17103471 | 0.82 | KIF11 (0.31) | KIF11 | |
| SCHEMBL27949956 | 0.82 | KIF11 (0.31) | KIF11 | |
| SCHEMBL17103322 | 0.79 | — | — | |
| SCHEMBL2250973 | 0.76 | KIF11 (0.37) | KIF11 | |
| SCHEMBL27083514 | 0.73 | KIF11 (0.30) | KIF11 | |
| SCHEMBL9841109 | 0.67 | SMN1; SMN2 (0.35) | KIF11KMT2A | |
| SCHEMBL27720322 | 0.67 | KIF11 (0.59) | KIF11KMT2A | |
| SCHEMBL5011652 | 0.67 | KIF11 (0.30) | KIF11 | |
| SCHEMBL601705 | 0.67 | KIF11 (0.30) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 778 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | CARLSSON JENS (SE) | 2024-06-27 | — | — | US | claimed |
| WO-2024118801-A1 | LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| CN-117751105-A | Substituted hydantoin compounds, process for their preparation and their use in the treatment and/or prophylaxis of coronavirus diseases | J·卡尔松 | 2024-03-22 | — | — | CN | claimed |
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. | 2024-03-21 | — | — | US | claimed |
| EP-4329883-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | Carlsson, Jens (SE) | 2024-03-06 | — | — | EP | claimed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | claimed |
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2023-09-28 | — | — | US | claimed |
| CN-111566109-B | 2,4,6, 7-tetrahydropyrazolo [4,3-d ] pyrimidin-5-one derivatives and related compounds for the treatment of vasculitis and inflammatory diseases | 爱杜西亚药品有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-116283773-A | Sinomenine amide derivative, and preparation method and application thereof | 安徽农业大学 | 2023-06-23 | — | — | CN | claimed |
| WO-2002022583-A2 | PYRIDINYL AMIDES AND IMIDES FOR USE AS FUNGICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-03-21 | — | — | WO | claimed |
| US-6300357-B1 | FOR THERAPY OF MYCOTIC DISEASE OF A HUMAN BEING AND AN ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | claimed |
| EP-1114028-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | Aventis Pharma Limited (GB) | 2001-07-11 | — | — | EP | claimed |
| EP-1056728-A1 | DIHYDRO-BENZO(1,4)OXAZINES AND TETRAHYDROQUINOXALINES | Aventis Pharma Limited (GB) | 2000-12-06 | — | — | EP | claimed |
| WO-2000039103-B1 | DIHYDRO-BENZO(1,4)OXAZINES AND TETRAHYDROQUINOXALINES | AVENTIS PHARMA LTD (GB) | 2000-09-28 | — | — | WO | claimed |
| US-6117821-A | COMPRISING HERBICIDES AND AGRONOMICALLY ACCEPTABLE CARRIERS; USE THEREOF AS BROAD SPECTRUM HERBICIDES WHICH ARE EFFECTIVE AGAINST BOTH MONOCOT AND DICOT WEED SPECIES IN BOTH PREEMERGENCE AND POSTEMERGENCE APPLICATIONS | ROHM AND HAAS COMPANY (US) | 2000-09-12 | — | — | US | claimed |
| WO-2000039103-A1 | DIHYDRO-BENZO(1,4)OXAZINES AND TETRAHYDROQUINOXALINES | AVENTIS PHARMA LIMITED (GB) | 2000-07-06 | — | — | WO | claimed |
| WO-2000015612-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | AVENTIS PHARMA LIMITED (GB) | 2000-03-23 | — | — | WO | claimed |
| EP-0185256-B1 | TRIAZOLE DERIVATES, THEIR PREPARATION AND THEIR USE AS PESTICIDES | CIBA-GEIGY AG (CH) | 1991-01-30 | — | — | EP | claimed |
| EP-0185256-A2 | Triazole derivates, their preparation and their use as pesticides | CIBA-GEIGY AG (CH) | 1986-06-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | KIF11 3377/4885KMT2A 1174/4885KDM5A 468/4885 |
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | TRPC5, REN, SLC5A1 | KIF11 2547/4885KMT2A 4776/4885KDM5A 2617/4885 |
| US-20240208970-A1 | SUBSTITUTED HYDANTOIN COMPOUNDS, METHODS FOR PREPARATION THEREOF AND USE THEREOF IN THE TREATMENT AND/OR PREVENTION OF A CORONA VIRUS DISEASE | FURIN, ACE, PEPD | KIF11 4841/4885KMT2A 726/4885KDM5A 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.